Eikon Therapeutics — Third Quarter 2026 Earnings Summary

Eikon Therapeutics reported third-quarter 2026 financial results, ending the period with $461.7 million in cash and cash equivalents, projecting an operational runway into the first quarter of 2028. The company advanced its clinical portfolio by dosing the first patient in the registrational TeLuRide-008 trial for EIK1001 in non-small cell lung cancer and submitting an IND application for the novel androgen receptor antagonist EIK1006. Updated clinical data presented at the 2026 ESMO Congress demonstrated strong efficacy for EIK1001 in combination therapies and promising activity for its selective PARP1 inhibitors and WRN helicase inhibitor program. Additionally, the company appointed Ching-Pin Chang as Chief Scientific Officer and reported a net loss of $86.1 million for the quarter.